Search
Nevada Paid Clinical Trials
A listing of 559 clinical trials in Nevada actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
205 - 216 of 559
Nevada is currently home to 559 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Las Vegas, Henderson, Reno and Carson City. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Recruiting
The purpose of this study is:
* To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose,
* To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine,
* To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/16/2025
Locations: GSK Investigational Site, Las Vegas, Nevada
Conditions: Respiratory Syncytial Virus Infections
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Las Vegas, Nevada
Conditions: Asthma
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Recruiting
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Vector Clinical Trials, Sparks, Nevada
Conditions: Diabetes Mellitus, Type 1
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Recruiting
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters.
The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to sever... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/16/2025
Locations: Vector Clinical Trials- Site Number : 8400004, Las Vegas, Nevada
Conditions: Colitis Ulcerative
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Oasis Clinical Research, Las Vegas, Nevada
Conditions: Acute Pain
A Study of XMT-1660 in Participants With Solid Tumors
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Early Breast Cancer
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
Recruiting
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2025
Locations: Jubilee Clinical Research, Inc, Las Vegas, Nevada
Conditions: MASH
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
Recruiting
53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
06/12/2025
Locations: Las Vegas Clinical Trials, North Las Vegas, Nevada
Conditions: Osteoarthritis (OA) of the Knee
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Recruiting
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
06/12/2025
Locations: DaVita Clinical Research, Las Vegas, Nevada
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
Recruiting
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.
After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Advancing Research International, LLC, Las Vegas, Nevada
Conditions: Thyroid Eye Disease
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
06/12/2025
Locations: Nevada Kidney Disease & Hypertension Center, Las Vegas, Nevada
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases